Myditin (Pridinol Mesilate)

Pridinol mesilate exerts central anticholinergic activity, blocking muscarinic receptors in the brainstem and spinal cord. This reduces excitatory cholinergic input to skeletal muscles, leading to a decrease in muscle tone and alleviation of involuntary contractions.

The dosage of Myditin is individualized by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for pridinol mesilate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified prescriber after evaluating the clinical situation.

To request Myditin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other centrally acting muscle relaxants such as baclofen or tizanidine, pridinol mesilate primarily exerts anticholinergic effects rather than GABA‑ergic or α‑2‑adrenergic mechanisms. This difference may influence the side‑effect profile, with less sedation but a higher likelihood of anticholinergic symptoms, making selection dependent on patient tolerance and comorbidities.

Myditin should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and sources of heat. Ensure the container is tightly closed to maintain stability throughout its shelf life.

Myditin is taken orally, usually with a glass of water. The tablet (or other oral dosage form) should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional. Administration timing (e.g., with meals) follows the prescriber’s guidance.

The most serious adverse reactions include severe allergic responses such as anaphylaxis, hepatotoxicity, cardiac arrhythmias, and rare cases of seizures or neutropenia. Patients experiencing rash, difficulty breathing, jaundice, irregular heartbeat, or unexplained fever should seek immediate medical attention.

Myditin is contraindicated in individuals with known hypersensitivity to pridinol mesilate or other anticholinergic agents. Caution is advised for patients with uncontrolled glaucoma, severe urinary retention, gastrointestinal obstruction, or significant hepatic impairment. The drug should also be avoided in anyone for whom a safer alternative is available, as determined by the prescriber.